Genfit (GNFTF) Stock Price, News & Analysis

Company Overview

Genfit S.A. is a France-based biopharmaceutical company focused on developing medicines and diagnostic solutions for metabolic, liver and rare diseases. The company’s research programs target conditions with significant unmet medical needs, including metabolic dysfunction-associated steatohepatitis (MASH), primary biliary cholangitis and other progressive liver disorders.

Genfit’s pipeline has included investigational therapies designed to address liver inflammation, fibrosis and related metabolic complications. The company also develops noninvasive diagnostic and prognostic technologies intended to support disease detection, patient stratification and treatment monitoring. Its activities span drug discovery, clinical development and partnerships with larger pharmaceutical companies.

Founded in 1999 and headquartered in Lille, France, Genfit operates primarily through research and development activities serving international pharmaceutical and healthcare markets. Its former lead drug candidate, elafibranor, was licensed to Ipsen and subsequently approved in the United States under the brand name Iqirvo for the treatment of primary biliary cholangitis. Pascal Prigent serves as Genfit’s chief executive officer.

Key Stats

• Today's Range: $15.75 to $15.75
• 50-Day Range: $10.75 to $16.50
• 52-Week Range: $4.14 to $16.50
• Volume: N/A
• Average Volume: 604 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Genfit Stock Analysis - MarketRank™

Genfit scored higher than 3% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Genfit.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Genfit is -23.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Genfit is -23.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Genfit has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Genfit does not currently pay a dividend.

Dividend Growth

Genfit does not have a long track record of dividend growth.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: N/A

News Sentiment

Genfit has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Genfit this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Genfit insiders have not sold or bought any company stock.

Percentage Held by Institutions

11.11% of the stock of Genfit is held by institutions.

Company Calendar

• Today: 9/26/2026
• Next Earnings (Estimated): 9/29/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:GNFTF
• CIK: N/A
• Web: www.genfit.com
• Phone: (332) 016-4000
• Fax: N/A
• Employees: 159
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A